Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27839523 | 0.88 | SLC1A1 (0.47) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL10201895 | 0.87 | MIF (0.46) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL10581091 | 0.82 | SMN1; SMN2 (0.41) | SLC1A1FOLH1TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL4421756 | 0.78 | CYP1A2 (0.52) | SLC1A1FOLH1PPARASLC1A3SLC1A2 | |
| SCHEMBL2808578 | 0.78 | CYP1A2 (0.52) | SLC1A1FOLH1PPARASLC1A3SLC1A2 | |
| SCHEMBL3496986 | 0.78 | CYP1A2 (0.52) | SLC1A1FOLH1PPARASLC1A3SLC1A2 | |
| SCHEMBL16058000 | 0.77 | SLC1A1 (0.48) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL27832950 | 0.77 | CYP1A2 (0.50) | SLC1A1FOLH1PPARASLC1A3SLC1A2 | |
| Water SCHEMBL27350729 | 0.77 | CYP1A2 (0.50) | SLC1A1FOLH1PPARASLC1A3SLC1A2 | |
| SCHEMBL30885167 | 0.76 | PPARG (0.58) | PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102365294-B | The dipeptide analogue of neurotrophic factor NGF and BDNF | UCHREZHDENIE ROSSIISKOI AKADEMII MEDITSYNSKIKH NAUKNAUCHNO-ISSLEDOVATELSKY INSTITUT FARMAKOLOGII IMENI V.V.ZAKUSOVA RAMN (RU) | 2016-02-17 | — | — | CN | disclosed |
| US-20130231480-A1 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GENEARREST LTD (IL) | 2013-09-05 | — | — | US | disclosed |
| EP-2596102-A2 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GeneArrest Ltd (IL) | 2013-05-29 | — | — | EP | disclosed |
| CN-102365294-A | Dipeptide mimetics of ngf and bdnf neurotrophins | UCHREZHDENIE ROSSIISKOI AKADEMII MEDITSYNSKIKH NAUK | 2012-02-29 | — | — | CN | disclosed |
| WO-2012011114-A2 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GENEARREST LTD (IL) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231480-A1 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | POLM, POLRMT, DDB1 | SLC1A1 3816/4885CA1 4239/4885CA2 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.